The Dow Jones Industrial Average fell 570.78 points to 52,843.47 in late trading on September 8, a 1.07% drop that looked worse than the broader market beneath the surface. The S&P 500 slipped 0.35% to 7,691.55, while the Nasdaq Composite declined just 0.27% to 26,435.53.
The split mattered. Dow Jones weakness was driven less by broad panic than by severe declines in a handful of high-priced healthcare and industrial names, especially Novartis, Amgen and Stryker. At the same time, chip, optical networking and energy stocks attracted fresh buying.
Brent crude near $99 a barrel added another layer to the session, pushing inflation and rate fears back to the front of the market. That combination produced a sharp rotation rather than a uniform risk-off selloff.
Key Facts
- The Dow Jones Industrial Average fell 570.78 points, or 1.07%, to 52,843.47, while the S&P 500 lost 27.05 points, or 0.35%, to 7,691.55.
- Novartis dropped 13.21% to $138.85 after late-stage trial setbacks, erasing roughly $40 billion in market value in one session.
- Amgen fell 9.01% to $397.83, putting the stock on pace for its worst single-day decline since 2016.
- Intel rose 8.16% to $103.61 after unveiling a $20 billion common stock offering aimed at funding manufacturing and AI-related expansion.
- Brent crude climbed to $99.22 a barrel at one point, while the 10-year Treasury yield traded near 4.80%.
Dow Jones Industrial Average
The Dow Jones Industrial Average told a more dramatic story than the rest of Wall Street because of how the index is built. Unlike market-cap-weighted benchmarks, the Dow is price-weighted, meaning steep moves in expensive components can have an outsized impact on the headline number. That arithmetic was on full display as Amgen, Stryker and Howmet Aerospace accounted for much of the decline.
Novartis set the tone for healthcare after two major pipeline disappointments in less than a week. Its pelacarsen program lowered lipoprotein(a), or Lp(a), but failed to reduce cardiovascular death, heart attack or stroke in a Phase 3 outcomes study. A separate setback in myotonic dystrophy type 1 added further pressure. The result was not only a sharp selloff in Novartis, but a broad repricing across biotech and drug developers with related scientific exposure.
At the same time, leadership rotated into sectors tied to physical infrastructure, AI hardware and energy supply. Intel, Coherent, CoreWeave, Lumentum and Qualcomm all gained sharply. Energy shares also strengthened as geopolitical risk in the Middle East sent oil prices higher and reinforced the market’s focus on supply security, inflation and interest rates.
The Dow’s 571-point drop was less a sign of market-wide retreat than a reminder that stock-specific shocks and rising oil can reshape the tape in a matter of hours.
Why Novartis and Amgen Moved the Market
Novartis was the biggest single shock. The failed pelacarsen outcomes study challenged a widely followed assumption that lowering Lp(a) would translate into fewer cardiovascular events. That does not end the scientific debate, but it forces investors to assign lower probabilities to similar pipeline assets until more evidence arrives.
Amgen became collateral damage because it is developing olpasiran, another Lp(a)-lowering candidate, with Phase 3 data expected in 2028. Even though the drugs are not identical, investors quickly marked down expectations for the commercial and clinical value of the entire category. Because Amgen is a high-priced Dow component, its nearly $40-per-share drop had an immediate mechanical effect on the index.
Implications for Investors
For investors, the session offered three clear signals. First, broad index moves can mask intense sector rotation. The relatively mild losses in the S&P 500 and Nasdaq compared with the Dow showed that money did not simply leave equities. It moved away from healthcare names facing clinical uncertainty and into semiconductors, optical networking, energy infrastructure and commodity-linked stocks.
Second, oil is becoming a more important macro variable again. Brent’s move toward $100 a barrel raises the risk that inflation stays sticky just as Treasury yields remain elevated. With the 10-year near 4.80% and the 30-year around 5.27%, richly valued software and long-duration growth stocks face renewed pressure from higher discount rates. That helps explain why hardware and industrial capacity plays outperformed software despite both being tied to the AI buildout.
Third, investors should watch whether this becomes a durable leadership shift. If crude remains elevated and economic data stay firm, markets may continue to favor companies tied to power, manufacturing, interconnects, copper and energy security. Healthcare, especially biotech with binary trial risk, could remain volatile as investors reassess valuation frameworks after the Novartis data. Upcoming inflation readings, weekly petroleum inventory data and any further developments around Middle East energy infrastructure will be key watch-points.
The next test for the market is whether higher oil and higher yields stay contained or spill into broader earnings expectations. If they do, rotation could intensify across sectors rather than fade after a single volatile session.